Cargando…
Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China
OBJECTIVE: IgG4-related disease (IgG4-RD) is an immune-mediated multi-organ, chronic and progressive disease. Therefore, we conducted a study to investigate the susceptibility of COVID-19 in IgG4-RD patients in Hubei province, and to characterize the clinical manifestation of COVID-19 in IgG4-RD pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228889/ https://www.ncbi.nlm.nih.gov/pubmed/32425259 http://dx.doi.org/10.1016/j.semarthrit.2020.04.015 |
_version_ | 1783534652034646016 |
---|---|
author | Chen, Yu Dong, Yuanji Cai, Shaozhe Ye, Cong Dong, Lingli |
author_facet | Chen, Yu Dong, Yuanji Cai, Shaozhe Ye, Cong Dong, Lingli |
author_sort | Chen, Yu |
collection | PubMed |
description | OBJECTIVE: IgG4-related disease (IgG4-RD) is an immune-mediated multi-organ, chronic and progressive disease. Therefore, we conducted a study to investigate the susceptibility of COVID-19 in IgG4-RD patients in Hubei province, and to characterize the clinical manifestation of COVID-19 in IgG4-RD patients. METHODS: A follow-up system that includes over 200 IgG4-RD patients across the country during the past ten years. A total of ninety-one patients with IgG4-RD who live in Hubei, China were identified and responded to our survey. Medical history, clinical symptoms, laboratory tests, CT imaging, and treatment were obtained through a standardized data collection form, and then independently reviewed by two investigators. RESULTS: 2 of 91 cases were infected with COVID-19. Both of them were classified as moderate type. The symptoms such as fever and cough and radiologic features were similar to other COVID-19 patients. Neither of them episode recurrent of IgG4-RD nor progressed to severe or critical condition of COVID-19 under the condition of continuous oral low-dose of glucocorticoids. Besides, patient 2 took a long time for SARS-CoV-2 nucleic acid to turn negative. CONCLUSION: IgG4-RD patients may belongs to the susceptible population of COVID-19 infection, and thus need more careful personal protection. Early identification and properly treatment are very important to prevent IgG4-RD patients with COVID-19 from progression to severe condition. |
format | Online Article Text |
id | pubmed-7228889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72288892020-05-18 Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China Chen, Yu Dong, Yuanji Cai, Shaozhe Ye, Cong Dong, Lingli Semin Arthritis Rheum Article OBJECTIVE: IgG4-related disease (IgG4-RD) is an immune-mediated multi-organ, chronic and progressive disease. Therefore, we conducted a study to investigate the susceptibility of COVID-19 in IgG4-RD patients in Hubei province, and to characterize the clinical manifestation of COVID-19 in IgG4-RD patients. METHODS: A follow-up system that includes over 200 IgG4-RD patients across the country during the past ten years. A total of ninety-one patients with IgG4-RD who live in Hubei, China were identified and responded to our survey. Medical history, clinical symptoms, laboratory tests, CT imaging, and treatment were obtained through a standardized data collection form, and then independently reviewed by two investigators. RESULTS: 2 of 91 cases were infected with COVID-19. Both of them were classified as moderate type. The symptoms such as fever and cough and radiologic features were similar to other COVID-19 patients. Neither of them episode recurrent of IgG4-RD nor progressed to severe or critical condition of COVID-19 under the condition of continuous oral low-dose of glucocorticoids. Besides, patient 2 took a long time for SARS-CoV-2 nucleic acid to turn negative. CONCLUSION: IgG4-RD patients may belongs to the susceptible population of COVID-19 infection, and thus need more careful personal protection. Early identification and properly treatment are very important to prevent IgG4-RD patients with COVID-19 from progression to severe condition. Published by Elsevier Inc. 2020-08 2020-05-16 /pmc/articles/PMC7228889/ /pubmed/32425259 http://dx.doi.org/10.1016/j.semarthrit.2020.04.015 Text en © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chen, Yu Dong, Yuanji Cai, Shaozhe Ye, Cong Dong, Lingli Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China |
title | Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China |
title_full | Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China |
title_fullStr | Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China |
title_full_unstemmed | Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China |
title_short | Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China |
title_sort | clinical characteristics of igg4-rd patients infected with covid-19 in hubei, china |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228889/ https://www.ncbi.nlm.nih.gov/pubmed/32425259 http://dx.doi.org/10.1016/j.semarthrit.2020.04.015 |
work_keys_str_mv | AT chenyu clinicalcharacteristicsofigg4rdpatientsinfectedwithcovid19inhubeichina AT dongyuanji clinicalcharacteristicsofigg4rdpatientsinfectedwithcovid19inhubeichina AT caishaozhe clinicalcharacteristicsofigg4rdpatientsinfectedwithcovid19inhubeichina AT yecong clinicalcharacteristicsofigg4rdpatientsinfectedwithcovid19inhubeichina AT donglingli clinicalcharacteristicsofigg4rdpatientsinfectedwithcovid19inhubeichina |